Does preventive vaccination with engineered tumor cells work in cancer-prone transgenic mice?

Cancer Gene Therapy

Volumn 5, Issue 2, 1998, Pages 92-100

  Morel, Arnaud ^a   De La Coste, Alix ^a   Fernandez, Nadine ^b   Berson, Alain ^a   Kaybanda, Michèle ^a   Molina, Thierry ^a   Briand, Pascale ^a   Haddada, Hédi ^b   Guillet, Jean Gérard ^a   Antoine, Bénédicte ^a   Viguier, Mireille ^a   Kahn, Axel ^a  

^a INSTITUT COCHIN   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Gene therapy; Hepatocellular carcinoma; Immunotherapy, active

Indexed keywords

CANCER VACCINE; VIRUS T ANTIGEN;

ANIMAL; ARTICLE; C57BL MOUSE; EXPERIMENTAL NEOPLASM; GENETIC TRANSDUCTION; GENETICS; MOUSE; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; CANCER VACCINES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; TRANSDUCTION, GENETIC;

EID: 0032016494     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Oettgen HF, Old LJ. In: DeVita VT, Hellman S, Rosenberg SA, eds. Biologic Therapy of Cancer. Philadelphia: Lippincott; 1991:87-119.
2. Tepper RI, Mule JJ. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther. 1994;5:53-164.
3. Hock H, Dorsch M, Kunzendorf U, et al. Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res. 1993;53:714-716.
4. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539-3543.
5. Allione A, Consalvo M, Nanni P, et al. Immunizing and curative potential of replicating and non-replicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor α, granulocyte-macrophages colony stimulating factor, and interferon-γ gene or admixed with conventional adjuvants. Cancer Res. 1994;54:6022-6026.
6. Armstrong CA, Botella R, Galloway TH, et al. Antitumor effects of GM-CSF production by melanoma cells. Cancer Res. 1996;56:2191-2198.
7. Gerard CM, Bruyns C, Delvaux A, et al. Loss of tumorigenicity and increased immunogenicity induced by interleukin-10 gene transfer in B16 melanoma cells. Hum Gene Ther. 1996;7:23-31.
8. Vieweg J, Rosenthal FM, Bannerji R, et al. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res. 1994; 54:1760-1765.
9. Colombo M, Forni G. Cytokine gene transfer into tumor inhibition and tumor therapy: where are we now? Immunol Today. 1994;15:48-51.
10. Hellstrom KE, Hellström I, Chen L. Can co-stimulated tumor immunity be therapeutically efficacious? Immunol Rev. 1995;145:123-145.
11. Heuer JG, Tucker-McClung T, Gonin R, et al. Retrovirus-mediated gene transfer of B7.1 and MHC class II converts a poorly immunogenic neuroblastoma into a highly immunogenic one. Hum Gene Ther. 1996;7:2059-2068.
12. Cavallo F, Giovarelli M, Gulino A, et al. Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol. 1992;149:3627-3635.
13. Regulatory issues: human gene therapy protocols. Hum Gene Ther. 1996;7:1064-1078.
14. Rodolfo M, Zilochi C, Melani C, et al. Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. J Immunol. 1996;157:5536-5542.
15. Porgador A, Tzehoval E, Vadai E. Combined vaccination with Major Histocompatibility Class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases. Cancer Res. 1995; 55:4941-4949.
16. Huang H, Chen SH, Kosai K, et al. Gene therapy for hepatocellular carcinoma: long-term remission of primary and metastatic tumors in mice by interleukin-2 gene therapy in vivo. Gene Ther. 1996;3:980-987.
17. Dubois N, Bennoun M, Allemand T, et al. Time-course development of differentiated hepatocarcinoma and lung metastasis in transgenic mice. J Hepatol. 1991;13: 227-239.
18. Antoine B, Levrat F, Vallet V, et al. Gene expression in hepatocyte-like lines established by targeted carcinogenesis in transgenic mice. Exp Cell Res. 1992;200:175-185.
19. Levrat F, Vallet V, Berbar T, et al. Influence of the content in transcription factors on the phenotype of mouse hepatocyte-like cell lines (mhAT). Exp Cell Res. 1993;209:1-10.
20. Roth C, Mir LM, Cressent M, et al. Inhibition de la croissance tumorale induite par l'injection de cellules histo-incompatibles produisant de l'interleukine 2. C R Acad Sci Paris. 1992;314:499-504.
21. Chu G, Sharp P. Transfection of cells in suspension with DNA calcium-phosphate precipitates. Gene. 1981;13:197-202.
22. Coligan JE, Kruisbeck AM, Margulies DH, et al. Current Protocols in Immunology. New York: Greene and Wiley Interscience.
23. Stratford-Perricaudet, Levrero M, Chasse JF, et al. Evaluation of the transfer and expression in mice of an enzyme coding gene using a human adenovirus vector. Hum Gene Ther. 1990;1:241-256.
24. Rosenberg SA. The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens. Annu Rev Med. 1996;47:481-491.
25. Romieu R, Lacabanne V, Kayibanda M, et al. Critical stages of growth regulation in transgenic mice harboring a hepatocellular carcinoma revealed by distinct patterns of tumor necrosis factor-alpha and transforming growth factor-beta mRNA production. Int Immunol. 1991;9:1405-1413.
26. Sedlacek HH. Vaccination for treatment of tumors: a critical comment. Crit Rev Oncogenesis 1994;5:555-587.
27. Lacabanne V, Viguier M, Guillet JG, et al. A wild-type p53 cytotoxic T cell epitope is presented by mouse hepatocarcinoma cells. Eur J Immimol. 1996;126:2635-2639.
28. Tepper RI, Coffman RL, Leden P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Sci. 1992;257:548-551.
29. Nabel GJ, Nabel EG, Yang Z, et al. Direct gene transfer with DNA liposome complexes in melanoma expression, biological activity and lack of toxicity in humans. Proc Natl Acad Sci USA. 1993;90:11307-11311.
30. Colombo MP, Rodolfo M. Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: do animal studies really support clinical trials? Cancer Immunol Immunother. 1995;41:2656-270.
31. Osanto S, Brouwenstyn N, Vaessen N, et al. Immunization with interleukin-2 transfected melanoma cells: a phase I-II study in patients with metastatic melanoma. Hum Gene Ther. 1993;4:323-334.
32. Paroli M, Perrone A, Bonavita MS, et al. Immunology of hepatocellular carcinoma. Int J Gastr. 1991;23:494-497.
33. Guo YJ, Wu MC. Local response in hepatocellular carcinoma and its clinical implications. Chin Med. 1988;101: 685-688.
34. Haruta I, Yanauchi K, Aruga A, et al. Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma: comparison between LAK cell and CTL therapy. J Immunother. 1996; 19:218-223.
35. Posselt AM, Barker CF, Tomaszevski JE. Induction of donor-specific unresponsiveness by intrathymic islet transplantation. Science. 1990;249:1293-1295.
36. Posselt AM, Barker CFD, Friedman AL, et al. Prevention of autoimmune diabetes in the BB rat by intrathymic transplantation at birth. Science. 1992;256:1321-1324.
37. Gilgenkrantz H, Duboc D, Juillard V, et al. Transient expression of genes transferred in vitro into heart using first-generation adenoviral vectors: role of the immune response. Hum Gene Ther. 1995;6:1265-1274.
38. Ilan Y, Attavar P, Takahashi M, et al. Induction of central tolerance by intrathymic inoculation of adenoviral antigens into the host thymus permits long-term gene therapy in Gunn rats. J Clin Invest. 1996;12:2640-2648.